Welcome to our dedicated page for Applied Therapeutics SEC filings (Ticker: APLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Applied Therapeutics, Inc. (APLT) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings give detailed insight into how the clinical-stage biopharmaceutical company reports its financial condition, pipeline progress, capital structure, and material corporate events related to its rare disease programs.
Investors use Forms 10-K and 10-Q to review Applied Therapeutics’ audited and quarterly financial statements, research and development spending, license and collaboration arrangements, and risk factor disclosures tied to its lead drug candidate govorestat (AT-007) and other programs. These reports also describe the company’s focus on CNS rare metabolic diseases, including Classic Galactosemia, CMT-SORD, and PMM2-CDG, and summarize key regulatory designations such as Orphan Drug and Rare Pediatric Disease status.
Form 8-K current reports are especially important for APLT. Recent 8-K filings describe the Agreement and Plan of Merger with Cycle Group Holdings Limited, including the tender offer structure, cash consideration and non-tradeable contingent value rights (CVRs), as well as the board’s recommendation to stockholders. Other 8-Ks cover the initiation of a strategic alternatives review, workforce reductions, at-the-market equity offering agreements, Nasdaq bid price notifications and listing transfers, leadership changes, and quarterly earnings press releases.
Users interested in insider and security-holder activity can also reference ownership-related filings (such as Forms 3, 4, and 5 when available) to understand how directors, officers, and major holders transact in APLT securities around key clinical or corporate milestones.
On Stock Titan, these Applied Therapeutics filings are updated in near real time as they appear on EDGAR. AI-powered tools can help summarize lengthy 10-K and 10-Q reports, highlight material sections of 8-Ks related to the Cycle merger, strategic reviews, or Nasdaq notices, and make it easier to interpret complex capital structure and contingent value right provisions. This allows readers to quickly grasp what each filing means for APLT’s financial position, regulatory path for govorestat, and the status of the proposed acquisition.
Applied Therapeutics, Inc. has filed a post-effective amendment to terminate its shelf registration on Form S-3 that originally covered up to $300,000,000 of securities, 38,250,000 shares of common stock issuable upon warrant exercise, and 31,735,731 resale shares.
The company completed a merger in which AT2B, Inc., a subsidiary of Cycle Group Holdings Limited, merged into Applied Therapeutics, leaving it as a private, indirect wholly owned subsidiary of Cycle Group. Because of this merger, the company is ending all offerings under the S-3 and deregistering any securities that remained unsold.
Applied Therapeutics, Inc. has filed a post-effective amendment to shut down a prior Form S-3 resale registration. The original shelf allowed selling stockholders to offer up to 14,285,714 shares of common stock, but the company has since completed a merger.
On February 3, 2026, a subsidiary of Cycle Group Holdings Limited merged with Applied Therapeutics, leaving Applied Therapeutics as a private company and an indirect wholly owned subsidiary of Cycle Group Holdings. Because of this change, the company is terminating all offerings under the S-3 and deregistering any shares that remained unsold, so there are no securities left registered under that statement.
Applied Therapeutics, Inc. is having its common stock removed from listing and registration on the Nasdaq Stock Market, as reflected in a Form 25 filed under Section 12(b) of the Exchange Act. Nasdaq states it has complied with its own rules and the SEC’s requirements for striking this class of securities from listing or effecting a voluntary withdrawal.
Applied Therapeutics, Inc. has been acquired by Cycle Group Holdings Limited through a completed tender offer and merger. Stockholders receive $0.088 in cash per share plus one contingent value right (CVR) that may pay up to an additional $0.40 per CVR and a share of any specified Closing Cash Payment if certain milestones are met. Approximately 79,518,606 shares, or about 51.56% of outstanding shares, were tendered, and total consideration for the equity was about $14.3 million. Following the merger, Applied Therapeutics became an indirect wholly owned subsidiary of Cycle Group, its Nasdaq-listed common stock will be delisted, SEC reporting will be terminated, and the board and leadership were replaced with Cycle Group’s designees.
Applied Therapeutics, Inc. reports the final results of a tender offer and the completion of its merger with an affiliate of Cycle Group Holdings Limited. Purchaser accepted for payment 79,518,606 shares of common stock, representing about 51.56% of shares outstanding when the offer expired.
Because the minimum tender condition was satisfied, the merger closed on February 3, 2026 without a stockholder vote under Delaware law. Each remaining share, with limited exceptions, was converted into the right to receive $0.088 in cash plus one contingent value right, which can pay up to an additional $0.40 in cash per CVR plus a potential pro rata Closing Cash Payment if specified milestones and cash levels are achieved.
Following the merger, Applied Therapeutics’ shares ceased trading on the Nasdaq Global Select Market and will be delisted. The new owners intend to terminate registration of the shares and suspend the company’s reporting obligations under the Exchange Act, effectively taking the company private.
Applied Therapeutics, Inc. has been acquired by AT2B, Inc., an indirect wholly owned subsidiary of Cycle Group Holdings Limited, through a cash tender offer followed by a merger. The offer paid $0.088 per share in cash plus one non-tradeable contingent value right (CVR) per share.
Each CVR provides a contractual right to receive up to four contingent cash payments totaling up to $0.40 per CVR, plus a pro rata portion of any specified Closing Cash Payment, if milestones defined in the CVR Agreement are achieved. After sufficient shares were tendered to meet the minimum condition, AT2B accepted and will pay for all validly tendered shares.
The merger was completed on February 3, 2026 under Section 251(h) of the Delaware General Corporation Law without a stockholder vote. All remaining eligible shares were converted into the right to receive the same offer price. Applied Therapeutics’ shares have ceased trading on the Nasdaq Global Select Market and will be delisted, with plans to terminate their Exchange Act registration and reporting obligations.
Applied Therapeutics filed an amendment updating shareholders on the tender offer by AT2B, Inc., an indirect wholly owned subsidiary of Cycle Group Holdings Limited. The offer values each share at a cash price of $0.088 plus one contingent value right, which may pay up to an additional $0.40 per right plus a potential pro rata cash amount tied to Closing Cash, subject to specified milestones and conditions.
The offer expiration has been extended to one minute after 11:59 p.m. Eastern time on February 2, 2026, unless further extended or earlier terminated under the merger agreement. As of one minute after 11:59 p.m. Eastern time on January 29, 2026, approximately 75,895,437 shares, including 2,429,370 shares subject to guaranteed delivery, had been validly tendered and not properly withdrawn, representing about 49.21% of the outstanding shares. Parent and Purchaser state that they expect to complete the offer promptly after the new expiration time, subject to remaining conditions in the merger agreement.
AT2B, Inc., an indirect wholly owned subsidiary of Cycle Group Holdings Limited, is amending its tender offer for all shares of Applied Therapeutics, Inc. common stock by extending the expiration time to one minute after 11:59 p.m. Eastern on February 2, 2026.
The offer price remains $0.088 in cash per share plus one non-tradeable contingent value right (CVR) per share, which may pay up to an additional $0.40 per CVR plus a pro rata share of any defined Closing Cash Payment upon specified milestones. As of one minute after 11:59 p.m. Eastern on January 29, 2026, 75,895,437 shares, including 2,429,370 shares subject to guaranteed delivery, had been validly tendered and not withdrawn, representing 49.21% of the outstanding shares.
Parent and Purchaser state they expect to consummate the offer promptly after the new expiration time, subject to satisfaction of the remaining conditions in the merger agreement, and they have issued a press release describing the extension.
Applied Therapeutics updated its recommendation statement for the pending tender offer by AT2B, Inc., an indirect subsidiary of Cycle Group Holdings. The offer values each share at $0.088 in cash plus one non‑tradeable contingent value right (CVR). Each CVR can pay up to an aggregate of $0.40 in cash, plus a pro rata share of certain additional cash if defined thresholds are met, all under a CVR Agreement with Equiniti Trust Company.
On January 29, 2026, the buyer extended the offer’s expiration to one minute after 11:59 p.m. Eastern time on that date. As of one minute after 11:59 p.m. Eastern time on January 28, 2026, approximately 68,353,893 shares, including 2,693,496 subject to guaranteed delivery, had been validly tendered and not withdrawn, representing 44.32% of outstanding shares. The parties state they expect to complete the offer promptly after the extended expiration, subject to remaining conditions in the merger agreement.
AT2B, Inc., an indirect wholly owned subsidiary of Cycle Group Holdings Limited, amended its tender offer for all outstanding shares of Applied Therapeutics, Inc. common stock to extend the expiration to one minute after 11:59 p.m. Eastern time on January 29, 2026.
The offer price is $0.088 per share in cash, plus one non‑tradeable contingent value right (CVR) per share. Each CVR provides the contractual right to receive up to four contingent cash payments totaling up to $0.40 per CVR plus a pro rata portion of any Closing Cash Payment, subject to the CVR Agreement conditions.
As of one minute after 11:59 p.m. Eastern time on January 28, 2026, approximately 68,353,893 shares, including 2,693,496 shares subject to guaranteed delivery, had been validly tendered and not properly withdrawn, representing 44.32% of the outstanding shares.
FAQ
What is the current stock price of Applied Therapeutics (APLT)?
What is the market cap of Applied Therapeutics (APLT)?
